223 related articles for article (PubMed ID: 29808267)
21. Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort.
Mallet J; Le Strat Y; Schürhoff F; Mazer N; Portalier C; Andrianarisoa M; Aouizerate B; Berna F; Brunel L; Capdevielle D; Chereau I; D'Amato T; Dubreucq J; Faget C; Gabayet F; Honciuc RM; Lançon C; Llorca PM; Misdrahi D; Rey R; Roux P; Schandrin A; Urbach M; Vidailhet P; Fond G; Dubertret C;
Eur Arch Psychiatry Clin Neurosci; 2019 Jun; 269(4):449-457. PubMed ID: 29396753
[TBL] [Abstract][Full Text] [Related]
22. Birth by cesarean section and schizophrenia: results from the multicenter FACE-SZ data-set.
Fond G; Bulzacka E; Boyer L; Llorca PM; Godin O; Brunel L; Andrianarisoa MG; Aouizerate B; Berna F; Capdevielle D; Chereau I; Denizot H; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Le Strat Y; Micoulaud-Franchi JA; Misdrahi D; Rey R; Richieri R; Roger M; Passerieux C; Schandrin A; Urbach M; Vidalhet P; Schürhoff F; Leboyer M;
Eur Arch Psychiatry Clin Neurosci; 2017 Sep; 267(6):587-594. PubMed ID: 27349652
[TBL] [Abstract][Full Text] [Related]
23. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
24. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort.
Godin O; Leboyer M; Schürhoff F; Llorca PM; Boyer L; Andre M; Andrianarisoa M; Aouizerate B; Berna F; Capdevielle D; Chereau I; Dorey JM; Dubertret C; Dubreucq J; Faget C; Lancon C; Leignier S; Mallet J; Misdrahi D; Passerieux C; Rey R; Roux P; Vidailhet P; Costagliola D; Fond G;
J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257079
[TBL] [Abstract][Full Text] [Related]
25. Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia.
Fond G; Faugere M; Faget-Agius C; Cermolacce M; Richieri R; Boyer L; Lançon C
Eur Arch Psychiatry Clin Neurosci; 2019 Dec; 269(8):879-886. PubMed ID: 30078128
[TBL] [Abstract][Full Text] [Related]
26. Towards an improved access to psychiatric rehabilitation: availability and effectiveness at 1-year follow-up of psychoeducation, cognitive remediation therapy, cognitive behaviour therapy and social skills training in the FondaMental Advanced Centers of Expertise-Schizophrenia (FACE-SZ) national cohort.
Dubreucq J; Ycart B; Gabayet F; Perier CC; Hamon A; Llorca PM; Boyer L; Godin O; Bulzacka E; Andrianarisoa M; Aouizerate B; Berna F; Brunel L; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Faget C; Mallet J; Misdrahi D; Passerieux C; Rey R; Richieri R; Schandrin A; Schürhoff F; Urbach M; Vidailhet P; Giraud-Baro E; Fond G;
Eur Arch Psychiatry Clin Neurosci; 2019 Aug; 269(5):599-610. PubMed ID: 30963264
[TBL] [Abstract][Full Text] [Related]
27. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
28. Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort.
Fond G; Boyer L; Andrianarisoa M; Godin O; Bulzacka E; Berna F; Brunel L; Coulon N; Aouizerate B; Capdevielle D; Chereau I; D'amato T; Denizot H; Dubertret C; Dubreucq J; Faget C; Leignier S; Mallet J; Misdrahi D; Rey R; Lancon C; Passerieux C; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Schurhoff F; Llorca PM;
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jul; 85():62-68. PubMed ID: 29678770
[TBL] [Abstract][Full Text] [Related]
29. Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.
Fond G; Boyer L; Boucekine M; Aden LA; Schürhoff F; Tessier A; Andrianarisoa M; Berna F; Brunel L; Capdevielle D; Chereau I; Mallet J; Denizot H; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Rey R; Richieri R; Passerieux C; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Misdrahi D;
Schizophr Res; 2017 Apr; 182():84-89. PubMed ID: 27789187
[TBL] [Abstract][Full Text] [Related]
30. Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.
Fond G; Godin O; Schürhoff F; Berna F; Bulzacka E; Andrianarisoa M; Brunel L; Aouizerate B; Capdevielle D; Chereau I; Coulon N; D'Amato T; Dubertret C; Dubreucq J; Faget C; Lançon C; Leignier S; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Boyer L; Llorca PM;
Psychiatry Res; 2018 Dec; 270():104-110. PubMed ID: 30245372
[TBL] [Abstract][Full Text] [Related]
31. Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences.
Dal Santo F; González-Blanco L; García-Álvarez L; de la Fuente-Tomás L; Velasco Á; Álvarez-Vázquez CM; Martínez-Cao C; Sáiz PA; García-Portilla MP; Bobes J
Sci Rep; 2020 Sep; 10(1):15963. PubMed ID: 32994460
[TBL] [Abstract][Full Text] [Related]
32. Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.
de Bartolomeis A; Prinzivalli E; Callovini G; D'Ambrosio L; Altavilla B; Avagliano C; Iasevoli F
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():356-366. PubMed ID: 28887181
[TBL] [Abstract][Full Text] [Related]
33. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.
Shah P; Iwata Y; Brown EE; Kim J; Sanches M; Takeuchi H; Nakajima S; Hahn M; Remington G; Gerretsen P; Graff-Guerrero A
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):11-22. PubMed ID: 31428862
[TBL] [Abstract][Full Text] [Related]
34. Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort.
Fond G; Boyer L; Leboyer M; Godin O; Llorca PM; Andrianarisoa M; Berna F; Brunel L; Aouizerate B; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Gabayet F; Mallet J; Misdrahi D; Rey R; Lancon C; Passerieux C; Roux P; Vidailhet P; Yazbek H; Schürhoff F; Bulzacka E;
Schizophr Res; 2018 May; 195():357-365. PubMed ID: 28974404
[TBL] [Abstract][Full Text] [Related]
35. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset.
Berna F; Misdrahi D; Boyer L; Aouizerate B; Brunel L; Capdevielle D; Chereau I; Danion JM; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lancon C; Mallet J; Rey R; Passerieux C; Schandrin A; Schurhoff F; Tronche AM; Urbach M; Vidailhet P; Llorca PM; Fond G;
Schizophr Res; 2015 Dec; 169(1-3):255-261. PubMed ID: 26589388
[TBL] [Abstract][Full Text] [Related]
36. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.
Kelly DL; Feldman S; Boggs DL; Gale E; Conley RR
Compr Psychiatry; 2010; 51(3):298-302. PubMed ID: 20399340
[TBL] [Abstract][Full Text] [Related]
37. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
38. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.
Suzuki T; Remington G; Mulsant BH; Uchida H; Rajji TK; Graff-Guerrero A; Mimura M; Mamo DC
Psychiatry Res; 2012 May; 197(1-2):1-6. PubMed ID: 22429484
[TBL] [Abstract][Full Text] [Related]
39. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
40. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
